NL-OMON24070尚未招募不适用
Research to (cost)effectiveness of paricalcitol in the treatment of secondary hyperparathyroidism
Het Sint Lucas Andreas ziekenhuis0 个研究点目标入组 114 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 114
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Hemodialysis patients older than 18 years
- •2. Secondary hyperparathyroidism
排除标准
- •1. Severe hypercalcemia (Ca2+ >2,65 mmol/L)
- •2. Severe liver failure
研究者
相似试验
尚未招募
不适用
Research to cost-effectiveness of paricalcitol of the treatment of secundary hyperparathyroidism at hemodialysis patientsNL-OMON24822Sint Lucas Andreas ziekenhuis114
进行中（未招募）
不适用
The (cost)effectiveness of paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients. - CEPSSecondary hyperparathyroidismMedDRA version: 9.1Level: LLTClassification code 10020708Term: Hyperparathyroidism secondaryEUCTR2007-006645-41-NLSint Lucas Andreas Hospital
招募中
4 期
The (cost)effectiveness of paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients.hyperparathyroidismincreased activity of the parathyroids1003394910029149NL-OMON31628Sint Lucas Andreas Ziekenhuis114
终止
4 期
Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis SubjectsSecondary HyperparathyroidismDialysisNCT00664430Abbott13
进行中（未招募）
不适用
Efficacy and safety of paricalcitol in the reduction of secondary hyperparathyroidism after kidney transplantation.Secondary hyperparathyroidism after renal transplantationMedDRA version: 16.0Level: PTClassification code 10020708Term: Hyperparathyroidism secondarySystem Organ Class: 10014698 - Endocrine disordersEUCTR2013-001326-25-ESFundación SENEFRO